Message

From: Hogan, Karen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=EB7DC31713D443F0A322F0163D8D7C73-HOGAN, KAREN]
Sent: 5/15/2015 9:18:54 PM
To: Jinot, Jennifer [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d0edf66a00054afe84f4ab5c5119562f-Jinot, Jennifer]
Subject: FW: S Jones comments on the RDX assessment
Attachments: RDX_Public Comment draft Toxicological Reviewt_MASTER_5-8-15_HERO_sjjcomments.docx; RDX_Public Comment draft Supplemental Information_3-2015_SRC tech edit_MASTER_TB_sjjcomments.docx; Summary of RDX hazards_5-14-15.docx; Potential text to use in Study Selection and Evaluation section_5-14-15.docx

fyi

From: Rieth, Susan
Sent: Friday, May 15, 2015 5:18 PM
To: Hogan, Karen; Persad, Amanda; Fite, Katherine; Blessinger, Todd
Cc: D'Amico, Louis; Subramaniam, Ravi; Brinkerhoff, Chris
Subject: FW: S Jones comments on the RDX assessment

Hi all,
I thought you might be interested in Samantha's comments on the RDX TR. (per her email below, more to follow....) We'll need to turn the TR around next week for ERC review. Lou and I plan to spend some time this weekend digesting Samantha's comments. If we need help with revisions, we'll be sure to let you know!
Thanks,
Sue

From: Jones, Samantha
Sent: Friday, May 15, 2015 12:33 AM
To: D'Amico, Louis; Rieth, Susan
Cc: Cogliano, Vincent; Perovich, Gina
Subject: S Jones comments on the RDX assessment

Hi all,

Attached here is the RDX toxicological review and supplemental information documents that incorporates edits and comments from my review. Deliberative Process / Ex. 5

Deliberative Process / Ex. 5

In the tox review, I have included a number of comment bubbles with various questions and recommendations, and in some places, alternative text or modifications. Please note that I was unable to fully complete my review as my brain has now stopped working in the capacity that is needed to adequately review an assessment. I have read all parts of the tox review **with the exception of the** 1) executive summary, 2) cancer text in hazard ID and dose-response chapters, and 3) ten pages (2-8 to 2-17) in Chapter 2 on noncancer dose-response. I went as far as I could today. I plan to send comments on those pieces as soon as I can.

In the supplemental, I have included a few comments and edits in various places in the earlier appendices. I did not review the PBPK and dose-response appendices.

A few items of note:

Deliberative Process / Ex. 5

If you have any questions or concerns, please let me know.

Enjoy!
Samantha